Equity Overview
Price & Market Data
Price: $4.46
Daily Change: -$0.03 / 0.67%
Daily Range: $4.46 - $4.60
Market Cap: $842,808,714
Daily Volume: 183,126
Performance Metrics
1 Week: 6.70%
1 Month: 16.75%
3 Months: -18.01%
6 Months: 34.74%
1 Year: 68.31%
YTD: 103.7%
Company Details
Employees: 119
Sector: Health technology
Industry: Biotechnology
Country:
Details
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.